Biosimilars
A biologic drug that closely resembles another biologic drug (called a reference drug) has been approved by the U.S. Food and Drug Administration (FDA). Biosimilars and reference drugs are made from living organisms, but they can be made in different ways and froms lightly different substances. To qualify as a biosimilar, a biologic drug must demonstrate that it is safe, works well, and functions like its reference drug.The drug should also be administered in the same manner, in the same dose and condition as the reference drug. A biosimilar drug must be approved by the FDA and may cost less than a reference drug.
Related Conference of Biosimilars
June 22-23, 2026
5th World Congress on Medicinal Chemistry and Computer Aided Drug Design
Paris, France
July 27-28, 2026
19th International Conference and Exhibition on Pharmacovigilance & Drug Safety
Rome, Italy
July 27-28, 2026
26th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry
Rome, Italy
August 20-21, 2026
27th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
London, UK
August 20-21, 2026
29th International Conference and Exhibition on Pharmaceutical Formulations
London, UK
August 20-21, 2026
32nd International Conference on Advanced Clinical Research and Clinical Trials
London, UK
November 19-20, 2026
14th International Conference and Exhibition on Natural Products and Medicinal Plants Research
Dubai, UAE
November 26-27, 2026
5th World Conference on Pharma Industry and Medical Devices
Zurich, Switzerland